Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease
- Conditions
- COPD
- Interventions
- Biological: Umbilical Cord Mesenchymal Stem Cells transplantationDrug: drug therapy according to Vietnamese MOHS procedure
- Registration Number
- NCT04433104
- Brief Summary
This trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) as a supplementary intervention in combination with standard COPD medication treatments in patients with moderate-to-severe COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 and Vietnam Ministry of Health's guidelines
- Detailed Description
The aim of this trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) as a supplementary intervention in combination with standard COPD medication treatments in patients with moderate-to-severe COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 and Vietnam Ministry of Health's guidelines. This matched case-control phase I/II trial is conducted at Vinmec Times City International Hospital, Hanoi, Vietnam between June 2020 and December 2021. In this study, 40 patients will be enrolled and assigned into two age-, gender- and COPD condition-matched groups, including a UC-MSC group and a control group. Both groups will receive standard COPD medication treatment based on the GOLD 2019 guidelines and the Vietnam Ministry of Health protocol. The UC-MSC group will receive two doses of thawed UC-MSC product with an intervention interval of 3 months. The primary outcome measures will include the incidence of prespecified administrationassociated adverse events (AEs) and serious adverse events (SAEs). The efficacy will be evaluated based on the absolute changes in the number of admissions, arterial blood gas analysis, lung function and lung fibrosis via CT scan and chest X-ray. The clinical evaluation will be conducted at baseline and 3, 6, and 12 months post
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- Diagnosed with COPD with stage B, C, or D according to GOLD 2019.
- Age between 40-75 years old.
- Both genders.
- Smoker or less than 6 months of smoking cessation time.
- Asthma and other pulmonary-related diseases and injuries (including lung tuberculosis, restrictive lung disease, idiopathic pulmonary fibrosis, or lung cancer).
- Acute and/or active infection.
- Cancer.
- Patients with complex cardiovascular diseases (including valvular heart disease, cardiomyopathy, arrhythmia, congenital heart disease, hypertrophy syndrome).
- Liver and kidney failure.
- Pregnancy.
- Patients with life expectancy less than 6 months due to concomitant illness.
- Under immunosuppressive treatment within 8 weeks of the first screening visit.
- Patient diagnosed diabetes with HbA1C>7%
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment (UC-MSC trasnplatation) drug therapy according to Vietnamese MOHS procedure 1 x 10\^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure control arm drug therapy according to Vietnamese MOHS procedure drug therapy according to Vietnamese MOHS procedure Treatment (UC-MSC trasnplatation) Umbilical Cord Mesenchymal Stem Cells transplantation 1 x 10\^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure
- Primary Outcome Measures
Name Time Method Adverse events and serious adverse events up to the 12-month period following treatment To assess safety, the number of AEs or SAEs during stem cell administration (72 h) at 3 months, 6 months, and 12 months after discharge will be evaluated
- Secondary Outcome Measures
Name Time Method Respiratory functions (FEV1/FVC) up to the 12-month period following treatment Respiratory functions (FEV1/FVC)
Respiratory functions (VC) up to the 12-month period following treatment Respiratory functions (VC)
inflammatory response (Pro-BNP) up to the 12-month period following treatment inflammatory response (Pro-BNP)
cytokine analysis from patients' plasma up to the 12-month period following treatment cytokine analysis from patients' plasma
Quality of Life using Georges Respiratory Questionnaire up to the 12-month period following treatment Georges Respiratory Questionnaire has scores range from 0 to 100, with higher scores indicating more limitations
inflammatory response (CRP) up to the 12-month period following treatment inflammatory response (CRP)
arterial blood gas analysis (pH) up to the 12-month period following treatment arterial blood gas analysis (pH)
Respiratory functions (FEV1) up to the 12-month period following treatment Respiratory functions (FEV1)
Respiratory functions (TLC) up to the 12-month period following treatment Respiratory functions (TLC)
Respiratory functions (DLCO) up to the 12-month period following treatment Respiratory functions (DLCO)
inflammatory response (Troponin-T) up to the 12-month period following treatment inflammatory response (Troponin-T)
Chest CT up to the 12-month period following treatment Changes of the lung fibrosis on chest CT at 6 months, and 12 months compared with baseline
arterial blood gas analysis (PaO2) up to the 12-month period following treatment arterial blood gas analysis (PaO2)
arterial blood gas analysis (PaCO2) up to the 12-month period following treatment arterial blood gas analysis (PaCO2)
arterial blood gas analysis (BE) up to the 12-month period following treatment arterial blood gas analysis (BE)
arterial blood gas analysis (HCO3-) up to the 12-month period following treatment arterial blood gas analysis (HCO3-)
Respiratory functions (RV) up to the 12-month period following treatment Respiratory functions (RV)
Respiratory functions (DLNO/DLCO) up to the 12-month period following treatment Respiratory functions (DLNO/DLCO)
modified medical research council up to the 12-month period following treatment modified medical research council (mMRC)
Trial Locations
- Locations (1)
Vinmec International Hospital Times City
🇻🇳Hà Nội, Hanoi, Vietnam